查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2133625

伴侶動物生物技術市場預測至2034年－全球分析（按產品類型、生物技術平台、動物類型、治療領域、通路、診斷技術、應用、最終用戶和地區分類）

Companion Animal Biotechnology Market Forecasts To 2034 - Global Analysis By Product Type, Biotechnology Platform, Animal Type, Therapeutic Area, Distribution Channel, Diagnostic Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球伴侶動物生物技術市場規模將達到 323 億美元，並在預測期內以 7.5% 的複合年成長率成長，到 2034 年將達到 575 億美元。

伴侶動物生物技術市場專注於用於改善寵物（尤其是犬貓）健康的先進生物技術。主要領域包括分子和基因診斷、疫苗、生物療法、再生醫學、細胞療法、基因技術和微生物組解決方案。市場擴張的促進因素包括寵物飼養量的增加、獸醫服務支出的成長、對預防性醫療保健日益重視以及對更早、更準確的疾病檢測的需求。基因組學、分子生物學、幹細胞研究和個人化獸醫學的進步正在拓展生物技術的應用範圍。獸醫研發投入的增加以及先進治療和診斷解決方案的日益普及，為伴侶動物生物技術供應商創造了更多機會。

慢性病和老齡化相關疾病的盛行率增加

犬貓慢性病和老齡化相關疾病負擔日益加重，推動了對創新生物技術解決方案的需求。伴侶動物越來越容易患上一些需要專業長期管理的疾病，例如關節退化、骨關節炎、癌症、發炎性疾病、軟組織損傷和慢性傷口。幹細胞、再生醫學、生物製藥、分子診斷和基因組學等技術正在拓展這些難治性疾病的治療選擇。再生醫學在肌肉骨骼疾病方面尤其具有吸引力，因為它除了傳統的症狀管理外，還具有促進組織修復的潛力。因此，伴侶動物疾病的日益複雜和普遍性正促使獸醫和飼主採用基於先進生物技術的療法。

生物技術獸醫學的高成本

高昂的生物技術解決方案可能會阻礙先進伴侶動物醫療保健的廣泛應用。基因分析、分子檢測、生物製藥、細胞療法和再生醫學療法通常需要複雜的檢測系統、專業人員以及額外的診斷和監測。與傳統療法相比，這些因素會增加獸醫護理的整體成本。許多寵物飼主可能無力或不願意支付如此昂貴的治療費用，尤其是在寵物保險覆蓋範圍有限的情況下。新興經濟體的獸醫院在購買先進設備和建立必要的技術能力方面也可能面臨資金障礙。因此，成本上升會降低治療的可及性，阻礙價格敏感型客戶群接受治療，並限制基於生物技術的獸醫解決方案的推廣。

基於微生物組的診斷和治療方法的發展

對伴侶動物體內微生物群落的科學認知不斷加深，正為生物技術發展開闢新的途徑。對腸道、口腔和皮膚微生物組的研究，揭示了微生物群落與免疫反應、發炎、消化以及多種疾病之間的關係。這些發現為基於微生物組的診斷提供了支持，該診斷能夠識別微生物系統的失衡，並促進益生菌、益生元、後生元和標靶微生物療法等乾預措施的開發。生技公司可以抓住這一機遇，建立微生物組檢測平台，並為寵物製定個人化的治療策略。隨著研究成果不斷湧現，臨床證據日益有力，定序成本不斷降低，微生物組技術有望從主要的研究應用轉向可操作的診斷和治療產品，從而拓展生物技術在伴侶動物領域的商業性潛力。

新興生物技術的臨床結果尚不確定

新興生物技術解決方案臨床療效的差異性可能對市場構成重大威脅。基於幹細胞、再生醫學、微生物組改造、基因技術和先進生技藥品的療法，其療效可能因品種、動物種類、疾病狀態或個體差異而有所不同。如果臨床療效不穩定或長期安全性尚不明確，獸醫可能會對推薦新技術猶豫不決。治療失敗和副作用的報告可能會進一步削弱專業人士和寵物飼主的信心。研發人員在建立標準化方案和證明可靠的臨床療效方面也可能面臨困難。因此，生物技術的應用可能仍局限於專業獸醫機構，而難以在一般伴侶動物醫療保健領域中整體應用。

新型冠狀病毒（COVID-19）的影響：

新冠疫情初期，由於獸醫服務受限、常規就診量下降、檢查室營運中斷以及運輸和供應鏈面臨挑戰，伴侶動物生物技術市場受到衝擊。因此，一些疫苗接種、診斷程序和非緊急治療被推遲。另一方面，疫情也為獸醫生物技術帶來了新的機遇，提高了人們對通用感染疾病和快速分子檢測重要性的認知。獸醫診斷實驗室加強了對動物體內SARS-CoV-2的檢測能力，並準備好支援更廣泛的公共衛生檢測。伴侶動物在動物檢測中佔據了相當大的比例。這些趨勢凸顯了獸醫診斷、疾病監測和「同一健康」理念的價值，為生物技術的長期創新提供了支持。

在預測期內，「診斷產品」細分市場預計將佔據最大的市場佔有率。

預計在預測期內，診斷產品領域將佔據最大的市場佔有率。這是因為基於生物技術的診斷對於伴侶動物疾病的早期發現、預防保健和治療進展監測至關重要。獸醫院越來越依賴分子檢測、免疫診斷、基因檢測、病理檢測和其他先進的診斷解決方案來識別感染疾病、慢性病、遺傳性疾病和老齡化相關疾病。寵物日益「人性化」也促使飼主定期帶寵物進行健康檢查和早期診斷。診斷產品的應用領域十分廣泛，包括常規檢查、疾病監測和專業獸醫護理，其應用也日益成熟。準確、快速和微創檢測方法的日益普及進一步鞏固了該領域的市場地位。

預計在預測期內，「精準獸醫」細分市場將實現最高的複合年成長率。

在預測期內，精準獸醫學領域預計將呈現最高的成長率。這是因為技術進步使獸醫能夠為犬、貓和其他伴侶動物提供日益個人化的醫療保健服務。基因組分析、分子檢測、生物資訊學和標靶治療策略有助於識別遺傳風險、分析疾病、制定治療方案並改善臨床管理。癌症和其他複雜慢性疾病病例的不斷增加進一步推動了對精準生物資訊和專業治療的需求。定序、計算分析和人工智慧的進步提高了基於精準醫學的獸醫解決方案的實用性。同時，飼主意識的提高以及對先進寵物醫療保健投入意願的增強，也推動了這些技術的更廣泛應用。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。這主要得益於該地區完善的獸醫基礎設施、強大的生物技術能力以及先進伴侶動物醫療技術的廣泛應用。大型動物用藥品公司、專業診斷實驗室、研究機構和先進獸醫設施的存在，為市場發展創造了有利環境。寵物飼養量的增加、獸醫支出的成長以及人們對疾病早期檢測和精準醫療日益成長的興趣，也推動了市場需求。美國憑藉其完善的獸醫網路、強大的研究生態系統以及在伴侶動物領域不斷擴展的分子、遺傳和先進診斷技術，仍然是重要的市場貢獻者。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於其伴侶動物醫療保健生態系統的持續快速發展。寵物飼養量的增加、對動物福利日益成長的關注、獸醫支出的上升以及獲得專業醫療保健服務的便利性提高，都在推動先進生物技術解決方案的應用。診斷實驗室的增加和獸醫學專業化的不斷深化，也帶動了對分子檢測、基因分析、預防醫學和先進疾病管理技術的需求。中國、印度、日本、韓國和澳洲等國家透過提升獸醫能力和加大對動物醫療保健的投資，為區域市場的擴張做出了貢獻。寵物照護市場的擴張，加上科技的進步，為伴侶動物生物技術供應商創造了巨大的成長潛力。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 我們根據客戶要求，提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球伴侶動物生物技術市場：依產品類型分類

  • 診斷產品
  • 疫苗
  • 生物製藥
  • 基因檢測產品
  • 細胞治療產品
  • 基因治療產品
  • 再生醫學產品
  • 基於微生物組的產品

第6章 全球伴侶動物生物技術市場：依生技平台分類

  • 基因組學
  • 蛋白質體學
  • 分子生物技術
  • 細胞生物技術
  • 基因編輯
  • 幹細胞技術
  • 微生物組生物技術
  • 合成生物學
  • 生物資訊學

第7章 全球伴侶動物生物技術市場：依動物類型分類

  • 狗
  • 貓
  • 兔子
  • 鳥
  • 小型哺乳動物
  • 爬蟲類
  • 異域伴侶動物

第8章 全球伴侶動物生物技術市場：依治療領域分類

  • 感染疾病
  • 腫瘤學
  • 皮膚病
  • 消化系統疾病
  • 整形外科和肌肉骨骼疾病
  • 心血管疾病
  • 神經病變
  • 腎臟和泌尿系統疾病
  • 呼吸系統疾病
  • 內分泌和代謝疾病
  • 免疫介導疾病
  • 遺傳性和先天性疾病
  • 眼科疾病

第9章 全球伴侶動物生物技術市場：依通路分類

  • 獸醫醫院和獸醫診所
  • 獸藥
  • 專業動物用藥品批發商
  • 線上獸藥零售商
  • 電子商務通路
  • 直接面對消費者的銷售管道

第10章 全球伴侶動物生物技術市場：依診斷技術分類

  • 分子診斷
  • 基於PCR的診斷方法
  • 次世代定序
  • 免疫診斷
  • 生物標記診斷
  • 基於病理學的診斷
  • 微生物組診斷

第11章 全球伴侶動物生物技術市場：依應用領域分類

  • 疾病診斷
  • 疾病預防
  • 疾病治療
  • 遺傳疾病篩檢
  • 精準獸醫學
  • 個人化獸醫學
  • 治療監測
  • 生殖生物技術

第12章 全球伴侶動物生物技術市場：依最終用戶分類

  • 動物醫院
  • 動物診所
  • 獸醫診斷檢測實驗室
  • 獸醫醫療中心
  • 獸醫醫學研究機構
  • 學術機構
  • 生技公司
  • 動物用藥品公司

第13章 全球伴侶動物生物技術市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第14章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第15章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第16章：公司簡介

  • Zoetis Inc.
  • IDEXX Laboratories, Inc.
  • Boehringer Ingelheim Animal Health
  • Elanco Animal Health Incorporated
  • Merck Animal Health
  • Virbac SA
  • Dechra Pharmaceuticals Limited
  • Antech Diagnostics, Inc.
  • Embark Veterinary, Inc.
  • Basepaws
  • Orivet Genetic Pet Care
  • Animal Genetics Inc.
  • VetStem, Inc.
  • Animal Cell Therapies, Inc.
  • FidoCure
  • ImpriMed, Inc.
  • Regenera Sciences
  • Vetigenics
Product Code: SMRC39495

According to Stratistics MRC, the Global Companion Animal Biotechnology Market is accounted for $32.3 billion in 2026 and is expected to reach $57.5 billion by 2034 growing at a CAGR of 7.5% during the forecast period. The Companion Animal Biotechnology market focuses on advanced biological technologies used to enhance healthcare for pets, especially dogs and cats. Key areas include molecular and genetic diagnostics, vaccines, biologic treatments, regenerative therapies, cell-based treatments, gene technologies, and microbiome solutions. Market expansion is supported by rising pet ownership, higher spending on veterinary services, increasing emphasis on preventive healthcare, and demand for earlier and more precise disease identification. Developments in genomics, molecular biology, stem-cell research, and personalized veterinary medicine are broadening biotechnology applications. Growing investment in veterinary research and the increasing availability of advanced therapeutic and diagnostic solutions are creating additional opportunities for companion-animal biotechnology providers.

Market Dynamics:

Driver:

Increasing Prevalence of Chronic and Age-Related Diseases

A growing burden of chronic and age-related illnesses in dogs and cats is creating a stronger need for innovative biotechnology solutions. Companion animals increasingly experience conditions such as joint degeneration, osteoarthritis, cancer, inflammatory disorders, soft-tissue injuries, and chronic wounds that can require specialized long-term management. Technologies including stem cells, regenerative therapies, biologics, molecular diagnostics, and genomic approaches are expanding the available options for these difficult conditions. Regenerative treatments are particularly attractive for musculoskeletal problems because they may support tissue repair in addition to conventional symptom management. Consequently, the increasing complexity and prevalence of companion-animal diseases are encouraging veterinarians and owners to adopt advanced biotechnology-based approaches.

Restraint:

High Cost of Biotechnology-Based Veterinary Treatments

Expensive biotechnology solutions can limit the broader adoption of advanced companion-animal healthcare. Genetic analyses, molecular testing, biologics, cell-based treatments, and regenerative procedures commonly involve sophisticated laboratory systems, specialized personnel, and additional diagnostic or monitoring requirements. These factors increase the overall cost of veterinary care compared with conventional treatment options. Many pet owners may be unable or unwilling to pay for high-priced therapies, especially where pet insurance provides limited reimbursement. Veterinary practices in emerging economies can also encounter financial barriers when acquiring advanced equipment and developing the necessary technical capabilities. As a result, elevated costs can reduce accessibility, constrain adoption among price-sensitive customers, and restrict the expansion of biotechnology-based veterinary solutions.

Opportunity:

Development of Microbiome-Based Diagnostics and Therapeutics

Greater scientific knowledge of microorganisms living in companion animals is opening new avenues for biotechnology development. Studies of intestinal, oral, and skin microbiomes are providing insights into relationships between microbial communities, immune responses, inflammation, digestion, and various diseases. These discoveries can support microbiome-based diagnostics that identify microbial imbalances and enable the development of interventions such as probiotics, prebiotics, postbiotics, and targeted microbial therapies. Biotechnology companies can capitalize by creating microbiome testing platforms and individualized treatment strategies for pets. As research generates stronger clinical evidence and sequencing becomes more affordable, microbiome technologies may transition from primarily research applications toward practical diagnostic and therapeutic products, expanding the commercial potential of companion-animal biotechnology.

Threat:

Uncertain Clinical Outcomes of Emerging Biotechnology

Variability in the clinical performance of emerging biotechnology solutions can pose a significant market threat. Treatments based on stem cells, regenerative medicine, microbiome modification, gene technologies, and advanced biologics may not produce uniform results among different breeds, species, disease conditions, or individual animals. When clinical outcomes are inconsistent or long-term safety remains uncertain, veterinarians may be reluctant to recommend newer technologies. Reports of treatment failures or adverse effects could further weaken confidence among professionals and pet owners. Developers may also encounter difficulties establishing standardized protocols and proving reliable clinical benefits. Consequently, biotechnology adoption could remain concentrated within specialized veterinary facilities instead of achieving broad acceptance across mainstream companion-animal healthcare.

Covid-19 Impact:

The COVID-19 outbreak initially disrupted the Companion Animal Biotechnology market by restricting veterinary services, reducing routine appointments, interrupting laboratory operations, and creating transportation and supply-chain challenges. Consequently, some vaccinations, diagnostic procedures, and non-emergency treatments were postponed. At the same time, the pandemic created new opportunities for veterinary biotechnology by increasing awareness of zoonotic infections and the importance of rapid molecular testing. Veterinary diagnostic laboratories adapted their capabilities to detect SARS-CoV-2 in animals and support broader public-health testing. Companion animals accounted for a substantial share of animal testing. These developments highlighted the value of veterinary diagnostics, disease surveillance, and One Health approaches, supporting longer-term biotechnology innovation.

The Diagnostic Products segment is expected to be the largest during the forecast period

The Diagnostic Products segment is expected to account for the largest market share during the forecast period, because biotechnology-based diagnostics are fundamental to early disease detection, preventive healthcare, and treatment monitoring in companion animals. Veterinary clinics increasingly rely on molecular tests, immunodiagnostics, genetic testing, pathology, and other advanced diagnostic solutions to identify infectious, chronic, hereditary, and age-related conditions. Growing pet humanization is also encouraging owners to pursue regular health screening and timely diagnosis. The broad applicability of diagnostic products across routine examinations, disease surveillance, and specialized veterinary care supports consistent utilization. Increasing adoption of accurate, rapid, and minimally invasive testing further strengthens the segment's market position.

The Precision Veterinary Medicine segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Precision Veterinary Medicine segment is predicted to witness the highest growth rate, because technological progress is enabling veterinarians to deliver increasingly individualized healthcare for dogs, cats, and other companion animals. Genomic analysis, molecular testing, bioinformatics, and targeted treatment strategies can help identify inherited risks, analyze diseases, guide therapeutic decisions, and improve clinical management. Rising cases of cancer and other complex chronic conditions are creating additional demand for precise biological information and specialized treatments. Advances in sequencing, computational analysis, and artificial intelligence are improving the practicality of precision-based veterinary solutions. At the same time, greater owner awareness and willingness to invest in sophisticated pet healthcare are supporting wider adoption of these technologies.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, because the region has well-developed veterinary infrastructure, strong biotechnology capabilities, and extensive adoption of advanced companion-animal healthcare technologies. The presence of major animal-health companies, specialized diagnostic laboratories, research institutions, and sophisticated veterinary facilities creates a favorable environment for market development. Increasing pet ownership, greater spending on veterinary care, and rising interest in early disease detection and precision medicine are also strengthening demand. The United States remains a major contributor because of its established veterinary networks, strong research ecosystem, and growing use of molecular, genetic, and advanced diagnostic technologies for companion animals.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, as the region's companion-animal healthcare ecosystem continues to develop rapidly. Increasing numbers of pet owners, greater attention to animal welfare, rising veterinary expenditure, and improved access to specialized healthcare are encouraging adoption of advanced biotechnology solutions. Growth in diagnostic laboratories and veterinary specialization is strengthening demand for molecular testing, genetic analysis, preventive care, and sophisticated disease-management technologies. Countries including China, India, Japan, South Korea, and Australia are contributing to regional expansion through improving veterinary capabilities and increasing investment in animal healthcare. The combination of expanding pet-care markets and technological advancement is creating significant growth potential for companion-animal biotechnology providers.

Key players in the market

Some of the key players in Companion Animal Biotechnology Market include Zoetis Inc., IDEXX Laboratories, Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Merck Animal Health, Virbac S.A., Dechra Pharmaceuticals Limited, Antech Diagnostics, Inc., Embark Veterinary, Inc., Basepaws, Orivet Genetic Pet Care, Animal Genetics Inc., VetStem, Inc., Animal Cell Therapies, Inc., FidoCure, ImpriMed, Inc., Regenera Sciences and Vetigenics.

Key Developments:

In June 2026, Elanco announced Elanco Ventures, backed by a $25 million multi-year commitment, to invest in and advance innovation across animal health. The platform is intended to support strategic investments in therapeutic advancements and supportive technologies, creating a partnership and investment pathway for biotechnology innovators relevant to animal health, including companion-animal applications.

In January 2026, Boehringer Ingelheim India entered into an agreement with Alivira Animal Health Limited for the distribution and promotion of its companion-animal portfolio in India.

Product Types Covered:

  • Diagnostic Products
  • Vaccines
  • Biologic Therapeutics
  • Genetic Testing Products
  • Cell Therapy Products
  • Gene Therapy Products
  • Regenerative Medicine Products
  • Microbiome-Based Products

Biotechnology Platforms Covered:

  • Genomics
  • Proteomics
  • Molecular Biotechnology
  • Cell Biotechnology
  • Gene Editing
  • Stem Cell Technology
  • Microbiome Biotechnology
  • Synthetic Biology
  • Bioinformatics

Animal Types Covered:

  • Dogs
  • Cats
  • Rabbits
  • Birds
  • Small Mammals
  • Reptiles
  • Exotic Companion Animals

Therapeutic Areas Covered:

  • Infectious Diseases
  • Oncology
  • Dermatological Disorders
  • Gastrointestinal Disorders
  • Orthopedic & Musculoskeletal Disorders
  • Cardiovascular Disorders
  • Neurological Disorders
  • Renal & Urinary Disorders
  • Respiratory Disorders
  • Endocrine & Metabolic Disorders
  • Immune-Mediated Disorders
  • Genetic & Hereditary Disorders
  • Ophthalmic Disorders

Distribution Channels Covered:

  • Veterinary Clinics & Hospitals
  • Veterinary Pharmacies
  • Specialty Animal Health Distributors
  • Online Veterinary Pharmacies
  • E-Commerce Channels
  • Direct-to-Consumer Channels

Diagnostic Technologies Covered:

  • Molecular Diagnostics
  • PCR-Based Diagnostics
  • Next-Generation Sequencing
  • Immunodiagnostics
  • Biomarker Diagnostics
  • Pathology-Based Diagnostics
  • Microbiome Diagnostics

Applications Covered:

  • Disease Diagnosis
  • Disease Prevention
  • Disease Treatment
  • Genetic Disease Screening
  • Precision Veterinary Medicine
  • Personalized Veterinary Medicine
  • Treatment Monitoring
  • Reproductive Biotechnology

End Users Covered:

  • Veterinary Hospitals
  • Veterinary Clinics
  • Veterinary Diagnostic Laboratories
  • Veterinary Specialty Centers
  • Veterinary Research Institutions
  • Academic Institutions
  • Biotechnology Companies
  • Animal Health Companies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Companion Animal Biotechnology Market, By Product Type

  • 5.1 Diagnostic Products
  • 5.2 Vaccines
  • 5.3 Biologic Therapeutics
  • 5.4 Genetic Testing Products
  • 5.5 Cell Therapy Products
  • 5.6 Gene Therapy Products
  • 5.7 Regenerative Medicine Products
  • 5.8 Microbiome-Based Products

6 Global Companion Animal Biotechnology Market, By Biotechnology Platform

  • 6.1 Genomics
  • 6.2 Proteomics
  • 6.3 Molecular Biotechnology
  • 6.4 Cell Biotechnology
  • 6.5 Gene Editing
  • 6.6 Stem Cell Technology
  • 6.7 Microbiome Biotechnology
  • 6.8 Synthetic Biology
  • 6.9 Bioinformatics

7 Global Companion Animal Biotechnology Market, By Animal Type

  • 7.1 Dogs
  • 7.2 Cats
  • 7.3 Rabbits
  • 7.4 Birds
  • 7.5 Small Mammals
  • 7.6 Reptiles
  • 7.7 Exotic Companion Animals

8 Global Companion Animal Biotechnology Market, By Therapeutic Area

  • 8.1 Infectious Diseases
  • 8.2 Oncology
  • 8.3 Dermatological Disorders
  • 8.4 Gastrointestinal Disorders
  • 8.5 Orthopedic & Musculoskeletal Disorders
  • 8.6 Cardiovascular Disorders
  • 8.7 Neurological Disorders
  • 8.8 Renal & Urinary Disorders
  • 8.9 Respiratory Disorders
  • 8.10 Endocrine & Metabolic Disorders
  • 8.11 Immune-Mediated Disorders
  • 8.12 Genetic & Hereditary Disorders
  • 8.13 Ophthalmic Disorders

9 Global Companion Animal Biotechnology Market, By Distribution Channel

  • 9.1 Veterinary Clinics & Hospitals
  • 9.2 Veterinary Pharmacies
  • 9.3 Specialty Animal Health Distributors
  • 9.4 Online Veterinary Pharmacies
  • 9.5 E-Commerce Channels
  • 9.6 Direct-to-Consumer Channels

10 Global Companion Animal Biotechnology Market, By Diagnostic Technology

  • 10.1 Molecular Diagnostics
  • 10.2 PCR-Based Diagnostics
  • 10.3 Next-Generation Sequencing
  • 10.4 Immunodiagnostics
  • 10.5 Biomarker Diagnostics
  • 10.6 Pathology-Based Diagnostics
  • 10.7 Microbiome Diagnostics

11 Global Companion Animal Biotechnology Market, By Application

  • 11.1 Disease Diagnosis
  • 11.2 Disease Prevention
  • 11.3 Disease Treatment
  • 11.4 Genetic Disease Screening
  • 11.5 Precision Veterinary Medicine
  • 11.6 Personalized Veterinary Medicine
  • 11.7 Treatment Monitoring
  • 11.8 Reproductive Biotechnology

12 Global Companion Animal Biotechnology Market, By End User

  • 12.1 Veterinary Hospitals
  • 12.2 Veterinary Clinics
  • 12.3 Veterinary Diagnostic Laboratories
  • 12.4 Veterinary Specialty Centers
  • 12.5 Veterinary Research Institutions
  • 12.6 Academic Institutions
  • 12.7 Biotechnology Companies
  • 12.8 Animal Health Companies

13 Global Companion Animal Biotechnology Market, By Geography

  • 13.1 North America
    • 13.1.1 United States
    • 13.1.2 Canada
    • 13.1.3 Mexico
  • 13.2 Europe
    • 13.2.1 United Kingdom
    • 13.2.2 Germany
    • 13.2.3 France
    • 13.2.4 Italy
    • 13.2.5 Spain
    • 13.2.6 Netherlands
    • 13.2.7 Belgium
    • 13.2.8 Sweden
    • 13.2.9 Switzerland
    • 13.2.10 Poland
    • 13.2.11 Rest of Europe
  • 13.3 Asia Pacific
    • 13.3.1 China
    • 13.3.2 Japan
    • 13.3.3 India
    • 13.3.4 South Korea
    • 13.3.5 Australia
    • 13.3.6 Indonesia
    • 13.3.7 Thailand
    • 13.3.8 Malaysia
    • 13.3.9 Singapore
    • 13.3.10 Vietnam
    • 13.3.11 Rest of Asia Pacific
  • 13.4 South America
    • 13.4.1 Brazil
    • 13.4.2 Argentina
    • 13.4.3 Colombia
    • 13.4.4 Chile
    • 13.4.5 Peru
    • 13.4.6 Rest of South America
  • 13.5 Rest of the World (RoW)
    • 13.5.1 Middle East
      • 13.5.1.1 Saudi Arabia
      • 13.5.1.2 United Arab Emirates
      • 13.5.1.3 Qatar
      • 13.5.1.4 Israel
      • 13.5.1.5 Rest of Middle East
    • 13.5.2 Africa
      • 13.5.2.1 South Africa
      • 13.5.2.2 Egypt
      • 13.5.2.3 Morocco
      • 13.5.2.4 Rest of Africa

14 Strategic Market Intelligence

  • 14.1 Industry Value Network and Supply Chain Assessment
  • 14.2 White-Space and Opportunity Mapping
  • 14.3 Product Evolution and Market Life Cycle Analysis
  • 14.4 Channel, Distributor, and Go-to-Market Assessment

15 Industry Developments and Strategic Initiatives

  • 15.1 Mergers and Acquisitions
  • 15.2 Partnerships, Alliances, and Joint Ventures
  • 15.3 New Product Launches and Certifications
  • 15.4 Capacity Expansion and Investments
  • 15.5 Other Strategic Initiatives

16 Company Profiles

  • 16.1 Zoetis Inc.
  • 16.2 IDEXX Laboratories, Inc.
  • 16.3 Boehringer Ingelheim Animal Health
  • 16.4 Elanco Animal Health Incorporated
  • 16.5 Merck Animal Health
  • 16.6 Virbac S.A.
  • 16.7 Dechra Pharmaceuticals Limited
  • 16.8 Antech Diagnostics, Inc.
  • 16.9 Embark Veterinary, Inc.
  • 16.10 Basepaws
  • 16.11 Orivet Genetic Pet Care
  • 16.12 Animal Genetics Inc.
  • 16.13 VetStem, Inc.
  • 16.14 Animal Cell Therapies, Inc.
  • 16.15 FidoCure
  • 16.16 ImpriMed, Inc.
  • 16.17 Regenera Sciences
  • 16.18 Vetigenics

List of Tables

  • Table 1 Global Companion Animal Biotechnology Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Companion Animal Biotechnology Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Companion Animal Biotechnology Market Outlook, By Diagnostic Products (2023-2034) ($MN)
  • Table 4 Global Companion Animal Biotechnology Market Outlook, By Vaccines (2023-2034) ($MN)
  • Table 5 Global Companion Animal Biotechnology Market Outlook, By Biologic Therapeutics (2023-2034) ($MN)
  • Table 6 Global Companion Animal Biotechnology Market Outlook, By Genetic Testing Products (2023-2034) ($MN)
  • Table 7 Global Companion Animal Biotechnology Market Outlook, By Cell Therapy Products (2023-2034) ($MN)
  • Table 8 Global Companion Animal Biotechnology Market Outlook, By Gene Therapy Products (2023-2034) ($MN)
  • Table 9 Global Companion Animal Biotechnology Market Outlook, By Regenerative Medicine Products (2023-2034) ($MN)
  • Table 10 Global Companion Animal Biotechnology Market Outlook, By Microbiome-Based Products (2023-2034) ($MN)
  • Table 11 Global Companion Animal Biotechnology Market Outlook, By Biotechnology Platform (2023-2034) ($MN)
  • Table 12 Global Companion Animal Biotechnology Market Outlook, By Genomics (2023-2034) ($MN)
  • Table 13 Global Companion Animal Biotechnology Market Outlook, By Proteomics (2023-2034) ($MN)
  • Table 14 Global Companion Animal Biotechnology Market Outlook, By Molecular Biotechnology (2023-2034) ($MN)
  • Table 15 Global Companion Animal Biotechnology Market Outlook, By Cell Biotechnology (2023-2034) ($MN)
  • Table 16 Global Companion Animal Biotechnology Market Outlook, By Gene Editing (2023-2034) ($MN)
  • Table 17 Global Companion Animal Biotechnology Market Outlook, By Stem Cell Technology (2023-2034) ($MN)
  • Table 18 Global Companion Animal Biotechnology Market Outlook, By Microbiome Biotechnology (2023-2034) ($MN)
  • Table 19 Global Companion Animal Biotechnology Market Outlook, By Synthetic Biology (2023-2034) ($MN)
  • Table 20 Global Companion Animal Biotechnology Market Outlook, By Bioinformatics (2023-2034) ($MN)
  • Table 21 Global Companion Animal Biotechnology Market Outlook, By Animal Type (2023-2034) ($MN)
  • Table 22 Global Companion Animal Biotechnology Market Outlook, By Dogs (2023-2034) ($MN)
  • Table 23 Global Companion Animal Biotechnology Market Outlook, By Cats (2023-2034) ($MN)
  • Table 24 Global Companion Animal Biotechnology Market Outlook, By Rabbits (2023-2034) ($MN)
  • Table 25 Global Companion Animal Biotechnology Market Outlook, By Birds (2023-2034) ($MN)
  • Table 26 Global Companion Animal Biotechnology Market Outlook, By Small Mammals (2023-2034) ($MN)
  • Table 27 Global Companion Animal Biotechnology Market Outlook, By Reptiles (2023-2034) ($MN)
  • Table 28 Global Companion Animal Biotechnology Market Outlook, By Exotic Companion Animals (2023-2034) ($MN)
  • Table 29 Global Companion Animal Biotechnology Market Outlook, By Therapeutic Area (2023-2034) ($MN)
  • Table 30 Global Companion Animal Biotechnology Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 31 Global Companion Animal Biotechnology Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 32 Global Companion Animal Biotechnology Market Outlook, By Dermatological Disorders (2023-2034) ($MN)
  • Table 33 Global Companion Animal Biotechnology Market Outlook, By Gastrointestinal Disorders (2023-2034) ($MN)
  • Table 34 Global Companion Animal Biotechnology Market Outlook, By Orthopedic & Musculoskeletal Disorders (2023-2034) ($MN)
  • Table 35 Global Companion Animal Biotechnology Market Outlook, By Cardiovascular Disorders (2023-2034) ($MN)
  • Table 36 Global Companion Animal Biotechnology Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 37 Global Companion Animal Biotechnology Market Outlook, By Renal & Urinary Disorders (2023-2034) ($MN)
  • Table 38 Global Companion Animal Biotechnology Market Outlook, By Respiratory Disorders (2023-2034) ($MN)
  • Table 39 Global Companion Animal Biotechnology Market Outlook, By Endocrine & Metabolic Disorders (2023-2034) ($MN)
  • Table 40 Global Companion Animal Biotechnology Market Outlook, By Immune-Mediated Disorders (2023-2034) ($MN)
  • Table 41 Global Companion Animal Biotechnology Market Outlook, By Genetic & Hereditary Disorders (2023-2034) ($MN)
  • Table 42 Global Companion Animal Biotechnology Market Outlook, By Ophthalmic Disorders (2023-2034) ($MN)
  • Table 43 Global Companion Animal Biotechnology Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 44 Global Companion Animal Biotechnology Market Outlook, By Veterinary Clinics & Hospitals (2023-2034) ($MN)
  • Table 45 Global Companion Animal Biotechnology Market Outlook, By Veterinary Pharmacies (2023-2034) ($MN)
  • Table 46 Global Companion Animal Biotechnology Market Outlook, By Specialty Animal Health Distributors (2023-2034) ($MN)
  • Table 47 Global Companion Animal Biotechnology Market Outlook, By Online Veterinary Pharmacies (2023-2034) ($MN)
  • Table 48 Global Companion Animal Biotechnology Market Outlook, By E-Commerce Channels (2023-2034) ($MN)
  • Table 49 Global Companion Animal Biotechnology Market Outlook, By Direct-to-Consumer Channels (2023-2034) ($MN)
  • Table 50 Global Companion Animal Biotechnology Market Outlook, By Diagnostic Technology (2023-2034) ($MN)
  • Table 51 Global Companion Animal Biotechnology Market Outlook, By Molecular Diagnostics (2023-2034) ($MN)
  • Table 52 Global Companion Animal Biotechnology Market Outlook, By PCR-Based Diagnostics (2023-2034) ($MN)
  • Table 53 Global Companion Animal Biotechnology Market Outlook, By Next-Generation Sequencing (2023-2034) ($MN)
  • Table 54 Global Companion Animal Biotechnology Market Outlook, By Immunodiagnostics (2023-2034) ($MN)
  • Table 55 Global Companion Animal Biotechnology Market Outlook, By Biomarker Diagnostics (2023-2034) ($MN)
  • Table 56 Global Companion Animal Biotechnology Market Outlook, By Pathology-Based Diagnostics (2023-2034) ($MN)
  • Table 57 Global Companion Animal Biotechnology Market Outlook, By Microbiome Diagnostics (2023-2034) ($MN)
  • Table 58 Global Companion Animal Biotechnology Market Outlook, By Application (2023-2034) ($MN)
  • Table 59 Global Companion Animal Biotechnology Market Outlook, By Disease Diagnosis (2023-2034) ($MN)
  • Table 60 Global Companion Animal Biotechnology Market Outlook, By Disease Prevention (2023-2034) ($MN)
  • Table 61 Global Companion Animal Biotechnology Market Outlook, By Disease Treatment (2023-2034) ($MN)
  • Table 62 Global Companion Animal Biotechnology Market Outlook, By Genetic Disease Screening (2023-2034) ($MN)
  • Table 63 Global Companion Animal Biotechnology Market Outlook, By Precision Veterinary Medicine (2023-2034) ($MN)
  • Table 64 Global Companion Animal Biotechnology Market Outlook, By Personalized Veterinary Medicine (2023-2034) ($MN)
  • Table 65 Global Companion Animal Biotechnology Market Outlook, By Treatment Monitoring (2023-2034) ($MN)
  • Table 66 Global Companion Animal Biotechnology Market Outlook, By Reproductive Biotechnology (2023-2034) ($MN)
  • Table 67 Global Companion Animal Biotechnology Market Outlook, By End User (2023-2034) ($MN)
  • Table 68 Global Companion Animal Biotechnology Market Outlook, By Veterinary Hospitals (2023-2034) ($MN)
  • Table 69 Global Companion Animal Biotechnology Market Outlook, By Veterinary Clinics (2023-2034) ($MN)
  • Table 70 Global Companion Animal Biotechnology Market Outlook, By Veterinary Diagnostic Laboratories (2023-2034) ($MN)
  • Table 71 Global Companion Animal Biotechnology Market Outlook, By Veterinary Specialty Centers (2023-2034) ($MN)
  • Table 72 Global Companion Animal Biotechnology Market Outlook, By Veterinary Research Institutions (2023-2034) ($MN)
  • Table 73 Global Companion Animal Biotechnology Market Outlook, By Academic Institutions (2023-2034) ($MN)
  • Table 74 Global Companion Animal Biotechnology Market Outlook, By Biotechnology Companies (2023-2034) ($MN)
  • Table 75 Global Companion Animal Biotechnology Market Outlook, By Animal Health Companies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.